Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.280
+0.060 (4.92%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 6.25, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 388.28% from the current stock price of 1.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 26, 2026.
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $9 | Buy | Reiterates | $9 | +603.13% | May 26, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $3 | Buy | Maintains | $3 | +134.38% | May 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $9 | Buy | Maintains | $9 | +603.13% | May 13, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $3 → $4 | Buy | Maintains | $3 → $4 | +212.50% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
17.94M
from 14.56M
Increased by 23.23%
Revenue Next Year
18.09M
from 17.94M
Increased by 0.87%
EPS This Year
-0.07
from -0.22
EPS Next Year
-0.09
from -0.07
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.4M | 74.9M | |
| Avg | 17.9M | 18.1M | |
| Low | 1.7M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 163.8% | 317.6% | |
| Avg | 23.2% | 0.9% | |
| Low | -88.1% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.07 | -0.09 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.